ArticleEuropean journal of pediatrics2026
A neonatal prognostic score for infants with congenital cytomegalovirus infection (cCMVnet Score).
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective was to identify risk factors for long-term sequelae in children with congenital cytomegalovirus (cCMV) infection and to develop a prognostic scoring system (cCMVnet score) to support individualized management. This retrospective study was conducted within the prospective European Registry of Children with cCMV and included 570 children born between 2011 and 2024 in 11 countries. Eligible participants had confirmed cCMV, early cranial ultrasound and brain MRI (≤ 90 days of life), and at least six months of follow-up. The primary outcome was sequelae, defined as sensorineural hearing loss (SNHL), motor impairment, epilepsy, or visual impairment. Predictors were identified using multivariable logistic regression with Elastic-Net selection, followed by development and internal validation of the score. Overall, 63.2% were symptomatic at birth and 28.9% developed sequelae, mainly SNHL (24.7%), motor impairment (8.2%), epilepsy (4.0%), and visual impairment (2.6%). Splenomegaly, severity of hearing loss and neuroimaging abnormalities (white matter changes, calcifications, ventriculomegaly, and cortical malformations/migration abnormalities) were significant predictors. The cCMVnet score showed strong discrimination (AUC 0.872). At a 2.99 point cut-off, sensitivity was 81.3%, specificity 85.3%, and negative predictive value 90.6%.Conclusions: The cCMVnet score enables accurate risk stratification beyond symptomatic status integrating clinical, audiological, and neuroimaging findings. External validation is needed before widespread implementation.
Indexed as
Identifiers
42667422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.